纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

Legend Biotech Corp.

NASDAQ:LEGN 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Ye Wang
Ye Wang is the founder of GenScript Corp. (2002), holding the title of Chief Operating Officer & Executive Director. Ms. Wang is also the founder of Genscript Biotech Corp. (2002), serving as President, COO & Executive Director. Current jobs include Director at CustomArray, Inc., Director at GenScript (Hong Kong) Ltd., Director at Bestzyme Biotech Corp., Director at Bestzyme Biotech Ltd., Director at Bestzyme Biotech USA, Inc., Director at Legend Biotech Corp. (since 2022), Director at Legend Biotech Ltd., Director at Genscript Biotech Ltd., Director at GenScript International Ltd., Director at GenScript USA, Inc., Director at Maplebio Nanjing Co. Ltd., Director at Probio Technology Ltd., President & Trustee at Ren-Shiu Foundation, Inc., and Partner at Nanjing Genbest Enterprise Management Center. Education history includes an undergraduate degree from Wuhan University (1990), a graduate degree from Wuhan University (1993), a graduate degree from the University of Bridgeport (2003), and an MBA from China Europe International Business School (2014).
Ye Wang
Ye Wang is the founder of GenScript Corp. (2002), holding the title of Chief Operating Officer & Executive Director. Ms. Wang is also the founder of Genscript Biotech Corp. (2002), serving as President, COO & Executive Director. Current jobs include Director at CustomArray, Inc., Director at GenScript (Hong Kong) Ltd., Director at Bestzyme Biotech Corp., Director at Bestzyme Biotech Ltd., Director at Bestzyme Biotech USA, Inc., Director at Legend Biotech Corp. (since 2022), Director at Legend Biotech Ltd., Director at Genscript Biotech Ltd., Director at GenScript International Ltd., Director at GenScript USA, Inc., Director at Maplebio Nanjing Co. Ltd., Director at Probio Technology Ltd., President & Trustee at Ren-Shiu Foundation, Inc., and Partner at Nanjing Genbest Enterprise Management Center. Education history includes an undergraduate degree from Wuhan University (1990), a graduate degree from Wuhan University (1993), a graduate degree from the University of Bridgeport (2003), and an MBA from China Europe International Business School (2014).
Ying Huang
Ying Huang currently works at Legend Biotech Corp., as Chief Executive Officer & Director from 2022 and Quanta Therapeutics, Inc., as Director from 2022. Dr. Huang also formerly worked at BofA Securities, Inc., as Managing Director & Head-Biotech Equity Research from 2014 to 2019, Credit Suisse Securities (USA) LLC (Broker), as Research Analyst, Schering-Plough Corp., as Principal Scientist, Wachovia Securities LLC, as Associate Analyst, Barclays Capital, Inc., as Vice President & Senior Analyst, Merrill Lynch, Pierce, Fenner & Smith, Inc., as Research Analyst from 2014 to 2019, and Gleacher & Co. Securities, Inc., as Research Analyst. Dr. Huang received his graduate degree and doctorate degree from The Trustees of Columbia University in The City of New York and undergraduate degree from the University of Science & Technology of China.
Corazon Dating Sanders
Corazon Dating Sanders currently works at AbGenomics International, Inc., as Director, Ultragenyx Pharmaceutical, Inc., as Independent Director from 2021, BeOne Medicines Ltd., as Independent Non-Executive Director from 2020, Legend Biotech Corp., as Independent Director, Altrubio, Inc., as Director from 2020, and Fred Hutchinson Cancer Research Center, as Trustee from 2022. Dr. Sanders also formerly worked at Fred Hutchinson Cancer Research Center, as Director, Transcelerate Biopharma, Inc., as Director, Molecular Templates, Inc., as Independent Director from 2019 to 2024, Genentech, Inc., as Senior Vice President & Global Head-PD Innovation from 2012 to 2017, and Juno Therapeutics, Inc., as Executive Vice President-Development Operations from 2017 to 2018. Dr. Sanders received her undergraduate degree and graduate degree from the University of the Philippines and graduate degree and doctorate degree from The Wharton School of the University of Pennsylvania.
Xiao Hui Ji
Xiao Hui Ji is the founder of Elpiscience Biopharma Ltd., serving as Chairman & Chief Executive Officer since 2017. Dr. Ji is the founder of Elpiscience Biopharmaceuticals, Inc., serving as Chairman & Chief Executive Officer since 2017. Dr. Ji was the founder of PharmaLegacy Laboratories (Shanghai) Co., Ltd., serving as Chief Executive Officer from 2008 to 2012. Dr. Ji is currently an Independent Director at Legend Biotech Corp. since 2020. Former positions include Director at The BayHelix Group from 2008 to 2013, Vice President-Business Development at Roche Holding AG from 2013 to 2016, and Partner at LAV Management Co., Ltd. from 2017 to 2020. Education includes an MBA from The University of Chicago, a doctorate from The University of Sheffield, and a doctorate from China Medical University.
Wai Man Yau
Wai Man Yau currently works at Legend Biotech Corp., as Independent Director, AMTD Strategic Capital Group, as Chief Financial Officer & Executive Director from 2016, C. & J. Clark International Ltd., as Chief Financial Officer from 2021, The Institute of Internal Auditors, as Member, and Hong Kong Institute of Certified Public Accountants, as Member from 2000. Mr. Yau also formerly worked at AMTD IDEA Group, as Vice Chairman & Chief Financial Office from 2016 to 2019, Protiviti Shanghai Co. Ltd., as Managing Director from 2006 to 2011, China General Education Group Ltd., as Independent Non-Executive Director from 2021 to 2022, PricewaterhouseCoopers LLP (Hong Kong), as Senior Manager from 2004 to 2006, Ernst & Young (China), as Partner from 2011 to 2016, and Arthur Andersen & Co. (Hong Kong), as Senior Manager. Mr. Yau received his Masters Business Admin degree in 2019 from The Hong Kong University of Science & Technology and undergraduate degree in 1997 from Lundquist College of Business.
Li Zhu
Li Zhu was the founder of Genetastix Corp., founded in 2000, serving as President & Chief Executive Officer from 2000 to 2005. Current jobs include Chairman at Probio Technology Ltd. since 2024, Director at Legend Biotech Corp. since 2020, Independent Director at Adagene, Inc. since 2023, Vice President-Marketing & Strategy at Nanjing Genscript Biotechnology Co., Ltd. since 2012, and Chief Strategy Officer at Genscript Biotech Corp. since 2010. Former jobs include Director-Molecular Biology at Takara Bio USA, Inc. from 1990 to 2000, Principal at Genentech, Inc. in 2006, Principal at Huyabio International LLC in 2010, Vice President-Research at Cathay Biotech, Inc. from 2006 to 2008, Vice President at Huya Biomedical Technology Shanghai Co., Ltd. in 2009, and Principal at Cathay Industrial Biotech Ltd. in 2008. Education includes a doctorate from Stanford University conferred in 1989 and an undergraduate degree from East China Normal University conferred in 1982.
Patrick J. Casey
Patrick J. Casey currently works at Legend Biotech Corp., as Independent Director from 2020, Duke University, as Professor from 2005, Duke University Health System, Inc., as Senior Vice Dean-Research, Research Centre of Excellence in Mechanobiology, as Member-Governing Board, and Duke-NUS Graduate Medical School Singapore, as Senior Vice Dean-Research. Dr. Casey also formerly worked at Duke University Center For Chemical Biology, as Director. Dr. Casey received his undergraduate degree from Augustana University and doctorate degree in 1986 from Brandeis University.
Fang Liang Zhang
Fang Liang Zhang was the founder of Nanjing Genscript Biotechnology Co., Ltd. (2004, Executive Director), GenScript Corp. (2002, Chairman, CEO & Executive Director), and Genscript Biotech Corp. (2002, Non-Executive Chairman). Current jobs include Chairman at Legend Biotech Corp. (2022), Director at GenScript (Hong Kong) Ltd., Executive Director at Genscript Biotech Corp. (2022), and Director at Nanjing Jinsirui Biotechnology Co., Ltd., Jinsikang Technology (Nanjing) Co., Ltd., Nanjing Bestzyme Bioengineering Co., Ltd., Hubei Bestzyme Biotechnology Co. Ltd., Shanghai Jingrui Biotechnology Co. Ltd., Bestzyme Biotech Corp., Bestzyme Biotech Hk Ltd., Bestzyme Biotech Ltd., Bestzyme Biotech USA, Inc., Nanjing Legend Biotech Co., Ltd., Legend Biotech HK Ltd., Legend Biotech Ltd., Genscript Biotech Ltd. (Non-Executive Director, 2022), GenScript International Ltd., and GenScript USA, Inc. Former jobs include Director at Legend Biotech Corp. (2015-2020) and Principal Scientist at Schering-Plough Holdings Ltd. (1995-2002). Education includes a doctorate from Duke University (1995), a graduate degree from Nanjing University (1987), and an undergraduate degree from Chengdu University of Technology (1984).
Fang Liang Zhang
Fang Liang Zhang was the founder of Nanjing Genscript Biotechnology Co., Ltd. (2004, Executive Director), GenScript Corp. (2002, Chairman, CEO & Executive Director), and Genscript Biotech Corp. (2002, Non-Executive Chairman). Current jobs include Chairman at Legend Biotech Corp. (2022), Director at GenScript (Hong Kong) Ltd., Executive Director at Genscript Biotech Corp. (2022), and Director at Nanjing Jinsirui Biotechnology Co., Ltd., Jinsikang Technology (Nanjing) Co., Ltd., Nanjing Bestzyme Bioengineering Co., Ltd., Hubei Bestzyme Biotechnology Co. Ltd., Shanghai Jingrui Biotechnology Co. Ltd., Bestzyme Biotech Corp., Bestzyme Biotech Hk Ltd., Bestzyme Biotech Ltd., Bestzyme Biotech USA, Inc., Nanjing Legend Biotech Co., Ltd., Legend Biotech HK Ltd., Legend Biotech Ltd., Genscript Biotech Ltd. (Non-Executive Director, 2022), GenScript International Ltd., and GenScript USA, Inc. Former jobs include Director at Legend Biotech Corp. (2015-2020) and Principal Scientist at Schering-Plough Holdings Ltd. (1995-2002). Education includes a doctorate from Duke University (1995), a graduate degree from Nanjing University (1987), and an undergraduate degree from Chengdu University of Technology (1984).
Tomas Jan Heyman
Tomas Jan Heyman currently works at Interlaken Therapeutics, Inc., as Chief Executive Officer, Exelixis, Inc., as Independent Director from 2023, Interuniversitair Micro-Electronica Centrum VZW, as Director from 2012, Primmune Therapeutics, Inc., as Director, and Legend Biotech Corp., as Independent Director from 2022. Mr. Heyman also formerly worked at Janssen Pharmaceutica NV, as Chairman & Chief Executive Officer from 2008 to 2016, Venatorx Pharmaceuticals, Inc., as Non-Executive Chairman from 2023 to 2024, Invivyd, Inc., as Independent Director from 2021 to 2024, OptiNose, Inc., as Independent Director from 2020 to 2025, CVRx, Inc., as Director, International Biomedical Research Alliance, as Director, Xilio Therapeutics, Inc., as Independent Director from 2022 to 2024, Akero Therapeutics, Inc., as Independent Director from 2020 to 2025, Crucell NV, as Member-Supervisory Board, Johnson & Johnson Innovation - JJDC, Inc., as President, Ortho Pharmaceutical Corp., as Vice President-Licensing, Janssen Global Services LLC, as Global Head-Business Development from 1992 to 2015, and Johnson & Johnson, as Global Head-Business Development from 2015 to 2019. Mr. Heyman received his graduate degree from Katholieke Universiteit Leuven and graduate degree from the University of Antwerp.
Li Mao
Li Mao currently works at Legend Biotech Corp., as Independent Director from 2022. Dr. Mao also formerly worked at Xcovery Holding, Inc., as Chief Executive Officer from 2018 to 2021, Livzon Pharmaceutical Group, Inc., as Chief Executive Officer in 2021, Betta Pharmaceuticals Co., Ltd., as Director, Chief Medical Officer & Senior VP from 2018 to 2021, Sino Biopharmaceutical Ltd., as Chief Medical Officer from 2021 to 2022, SciClone Pharmaceuticals (China) Co. Ltd., as Chief Medical Officer from 2022 to 2025, Johnson & Johnson, as Vice President from 2016 to 2018, The University of Texas M.D. Anderson Cancer Center, as Professor from 2004 to 2009, and the University of Maryland Baltimore County, as Professor from 2009 to 2016. Dr. Mao received his doctorate degree from Nanjing Medical University.
Peter Salovey
Peter Salovey is the founder of Yale Center For Emotional Intelligence. Current jobs include Director at The Paul Mellon Centre for Studies in British Art, Independent Director at Legend Biotech Corp. starting in 2024, President of Yale University Endowment, Dean of Yale Graduate School of Arts & Sciences, Dean of Yale College, Trustee of Yale New Haven Health Services Corp., Trustee of Yale-New Haven Hospital, Inc., and Ex-Officio Trustee of Yale-China Association, Inc. Former job includes President & Sterling Professor at Yale University from 2013 to 2024. Education includes undergraduate and graduate degrees from Stanford University conferred in 1980, and graduate and doctorate degrees from Yale University conferred in 1986.